No Data
Could The Market Be Wrong About Guangxi LiuYao Group Co., Ltd (SHSE:603368) Given Its Attractive Financial Prospects?
Guangxi LiuYao Group (603368.SH): Some fundraising investment projects have been completed and the surplus fundraising will be permanently used to supplement working capital.
On December 13, Gelonghui丨Guangxi LiuYao Group (603368.SH) announced that the company’s publicly issued convertible bonds fundraising investment projects (hereinafter referred to as "funding projects") "Nanning Traditional Chinese Medicine Decoction Pieces Production Capacity Expansion Project" and "Chain Pharmacy Expansion Project" have been completed and reached the intended usable status. The "supplementary working capital" has been fully utilized, and the company will conclude the aforementioned funding projects. To meet the company’s working capital needs for daily production and operations, the company plans to allocate a total of 57.2102 million yuan of unused funds from the aforementioned projects (the actual amount is based on the balance of the special fundraising account on the day the funds are transferred).
Not recognized by the capital markets? Guangxi Liuyao Group: The company's stock price does not match its value | Direct coverage of the earnings conference.
1. At the earnings conference, the chairman of guangxi liuyao group, Zhu Chaoyang, stated that the company's market cap, stock price, and company value are not aligned; 2. The company secretary Xu Yang stated that the company will improve the issue of high accounts receivable through measures such as strengthening the assessment of collection indicators for business personnel; 3. Xu Yang introduced the progress of the company's AI application business in response to investors' concerns.
Guangxi Liuyao Group (603368.SH): is actively exploring the development of international trade in traditional Chinese medicine.
Geronghui November 1st | guangxi liuyao group (603368.SH) stated on the interactive platform that the company is leveraging guangxi's geographical advantage facing ASEAN, actively exploring the international trade of traditional chinese medicine.
Guangxi Liuyao Group Co., Ltd. Report for the Third Quarter of 2024
Guangxi Liuyao Group (603368.SH) released its performance for the first three quarters, with a net income of 0.716 billion yuan, a year-on-year growth of 6.13%.
Guangxi Liuyao Group (603368.SH) released its third quarter report for 2024, achieving revenue of 15...
Investors Aren't Buying Guangxi LiuYao Group Co., Ltd's (SHSE:603368) Earnings
